I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Johns Hopkins neurology and neurosurgery research brings together some of the world’s most creative and curious minds who, together are working toward cures for devastating diseases such as brain cancer, Parkinson’s disease, ALS and dementia, while broadening our understanding of the most complex organ system in the body.
The Spinal Column Surgical Outcomes Laboratory aims to improve the neurological outcomes and functional capacity of patients undergoing spinal surgery. We collect large-scale retrospective patient databases and prospective patient registries to report high-quality data relating to the outcomes of neurosurgical operations. The laboratory participates in the National neurosurgical Quality and Outcomes Database (N2QOD). This multi-institutional collaboration has set forth a 3-year prospective study to benchmark quality and surgical outcome measures across several academic institutions. The Spinal Column Surgical Outcomes Laboratory specializes in biostatistical analysis of large-scale clinical databases, studying the outcomes of traditional and novel spinal procedures, quality control and cost-effectiveness research and clinical trials relating to spinal surgery outcomes.
The Johns Hopkins comprehensive Subependymoma and Ependymoma Research Center divideS its efforts into three areas: basic science, translational research and clinical practice. Each division works separately but shares findings and resources openly with each other and our collaborators. The goal of our united efforts is to optimize current treatments to affect the care received by patients with subependymomas and ependymomas. Also, our clinical, translational and basic science teams work to develop novel therapies to improve and extend the lives of those with these rare tumors.
The Ted Dawson Laboratory uses genetic, cell biological and biochemical approaches to explore the pathogenesis of Parkinson's disease (PD) and other neurologic disorders. We also investigate several discrete mechanisms involved in cell death, including the role of nitric oxide as an endogenous messenger, the function of poly (ADP-ribose) polymerase-1 and apoptosis inducing factor in cell death, and how endogenous cell survival mechanisms protect neurons from death.
Led by Dr. Chetan Bettegowda, our lab uses genetic analysis, biomarkers and patient outcome data to identify better ways to diagnose and treat disease. We research a variety of neurological conditions, including central nervous system tumors, trigeminal neuralgia and traumatic brain and spinal injuries.
The Calabresi Lab is located in the department of Neurology at the Johns Hopkins University School of Medicine. Our group investigates why remyelination occasionally fails following central nervous system demyelination in diseases like multiple sclerosis. Our primary focus is on discovering the role of t-cells in promoting or inhibiting myelination by the endogenous glial cells.
Five to 35 percent of spine fusionprocedures fail, even when using the gold standard treatment of grafting bone from the patient's own iliac crest. Fusion failure, otherwise known as pseudoarthrosis, is a major cause of failed back surgery syndrome (FBSS) and results in significant pain and disability, increasing the need for additional procedures and driving up health care costs. The ultimate goal of the Spinal Fusion Laboratory is to eliminate pseudoarthrosis by using animal models to study various strategies for improving spinal fusion outcomes, including delivery of various growth factors and biological agents; stem cell therapies and tissue engineering approaches.
We are exploring whether anodal tDCS when administered in combination with spelling, naming, or working memory therapy can improve language performance of PPA and MCI participants at least in the short term more than behavioral therapy alone. We are also investigating whether and how tDCS alters the neuropeptide signature in participants with PPA and MCI. We use proton magnetic resonance spectroscopy (1H-MRS) to monitor neuropeptide concentrations at the areas of stimulation. We hypothesize that tDCS will stabilize the decline of specific neuropeptides, but only in those areas of the brain where tDCS effectively results in more efficient gains in language compared to language therapy alone (with sham tDCS). Study results may help optimize future intervention in individuals with PPA and MCI by providing treatment alternatives in a neurodegenerative condition with no proven effective treatment. A better understanding of the therapeutic and neuromodulatory effects of tDCS in PPA and MCI will offer insight into ways of impeding neurodegeneration that may improve quality of life for individuals with PPA and MCI and may provide insights into the mechanisms of this treatment for augmenting therapy for stroke as well.
Improved acute stroke care means that more patients are surviving. Unfortunately, up to 60 percent of stroke survivors suffer disability in arm or leg use, and 30 percent need placement in a longer term care facility. Recovering motor skills after stroke is essential to rehabilitation and the restoration of a meaningful life. Therefore, there is an urgent need to develop innovative new approaches to rehabilitation. Most recovery from motor impairment after stroke occurs in the first month and is largely complete by three months. Improvement occurs independently of rehabilitative interventions (for example, physical and occupational therapy), which predominantly target function through compensatory strategies that do not constitute true recovery. Dr. Zeiler and his team are conducting research to uncover how to augment and prolong this critical window of time.
Request an Appointment
Adult Neurology: 410-955-9441
Pediatric Neurology: 410-955-4259
Adult Neurosurgery: 410-955-6406
Pediatric Neurosurgery: 410-955-7337
Already a Patient?
Traveling for Care?
Whether you're crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.